Biomarker are biological marker that is an indicator of normal biological processes, pathogenic cycle or pharmacological reactions to a therapeutic treatment. Biomarkers in Alzheimers are neurochemical indicators used to diagnose the presence of disease. Here, this biological marker helps in identifying the disease in much early state. beta amyloid (Abeta) is an indicator to Alzheimer’s disease. amyloid precursor protein on proteolytic cleavage, A-beta peptide is released, some Abeta peptides that are solubilized are distinguished in CSF and blood plasma which makes AB peptides a promising possibility for bio-marker. Beta-amyloid biomarker indicates 80% or above specificity, in differentiating Alzheimers from dementia. It is assumed that beta-amyloid as a biomarker will give a future to Alzheimers disease.
Related conference: Alzheimers Conference | Alzheimers Congress | Alzheimers Conferences | Dementia Conference | Dementia Congress |Dementia Conferences | Neurology Conference | Neurology Congress | Neurology Conferences | Neuro Disorders Conferences | Neuroscience Conference | Neuroscience Conferences
Related associations: Alzheimers Association and Alzheimer's Foundation of America, Alzheimers drug discovery, Alzheimers society of Canada, Alzheimer disease International, Alzheimers foundation of America, Lewy Body Dementia Association , Cure Alzheimers fund , Alzheimers Europe Parkinson Society Canada, American Association of Neurological Surgeons, American Academy of Neurology, World Federation of Neurology , Stroke Association, Spanish Society of Neurology, American Academy of Neurology, Alzheimers Disease International, Association of Parkinsonism and Related Disorders, World Federation of Neurology
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
